Abstract
Virus infections elicit long-term IgG antibody and memory responses. Human cytomegalovirus (HCMV) is widespread in humans and disseminates despite the presence of virus-specific antibodies. Here, we report that the HCMV Fcγ-binding glycoprotein 34 (gp34) modulates humoral immunity by binding to IgG⁺ memory B cells. gp34-B cell receptor (BCR) interaction initiates activation of the PDK1/AKT/mTOR/S6 pathway and BCR internalization in a SYK-independent manner. Prolonged stimulation also induces B-cell activation via upregulation of CD69 and CD86. In a T-cell-dependent response, however, interaction with gp34 blocks B-cell proliferation, differentiation into plasmablasts, and soluble IgG production, while stimulating TNF-α secretion. Through gp34 stimulation on IgG⁺ B cells, neighboring IgM⁺ and IgA⁺ B cells are likewise impaired in proliferation, plasmablast formation, and immunoglobulin secretion. In summary, gp34 specifically interacts with IgG⁺ memory B cells, inducing a hyporesponsive state across the B-cell compartment through direct and indirect regulation. This reveals a novel mode of viral evasion from B-cell responses by suppressing secondary immunity.
Introduction
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus that establishes lifelong persistence in the majority of the global population. While typically asymptomatic in healthy hosts, HCMV poses a significant threat to immunocompromised individuals and is a leading cause of congenital infections. A defining characteristic of HCMV is its ability to disseminate and reactivate even in the presence of a robust host immune response, including high titers of neutralizing antibodies.
Historically, HCMV research has focused on viral proteins that act as "decoy" Fc receptors (vFcγRs), which bind the constant region of host antibodies to interfere with effector functions like Natural Killer (NK) cell-mediated clearance. However, the direct impact of these viral proteins on the B cells themselves—the very source of humoral immunity—remained unexplored. This study identifies HCMV glycoprotein 34 (gp34) as a key mediator of immune evasion that directly targets and suppresses the memory B cell compartment.
Methods
To characterize the interaction between gp34 and the host immune system, researchers employed a combination of viral and recombinant protein models.
- Protein Models: Experiments utilized purified HCMV virions and a soluble recombinant version of the gp34 ectodomain (gp34₁₋₁₇₉). A mutant version (gp34₁₋₁₇₉W65F), incapable of antibody binding, served as a negative control.
- Cellular Analysis: Human peripheral blood mononuclear cells (PBMCs) from healthy donors and established B cell lines (Daudi, RPMI 8866) were analyzed.
- Binding and Signaling: Flow cytometry and phosphoflow cytometry were used to determine cellular targets and track the activation of intracellular signaling cascades (e.g., SYK, Lyn, AKT, mTOR).
- Functional Assays: B cells were stimulated with CD40L and IL-21 to mimic T-cell help. Proliferation, differentiation into plasmablasts, and antibody secretion (measured by ELISA) were assessed in the presence or absence of gp34.
Results
Specific Targeting of IgG+ Memory B Cells
The study found that gp34 does not bind indiscriminately to all B cells. Instead, it exhibits high specificity for the B cell receptor (BCR) of IgG⁺ memory B cells, which constitute approximately 15% of the total human B cell population. Naive B cells and those expressing IgM, IgD, or IgA were notably ignored by the viral protein.
Unconventional Signaling and BCR Internalization
Upon binding to the IgG-BCR, gp34 triggers a unique intracellular signaling pathway. Unlike typical antigen-induced BCR activation, which relies heavily on the kinase SYK, gp34-mediated signaling bypasses SYK. Instead, it activates the PDK1/AKT/mTOR/S6 pathway. This interaction leads to the rapid internalization of the BCR, effectively removing the cell's primary sensor for detecting the virus. While this process induces some markers of activation (CD69, CD86), it ultimately leaves the cell in a "hyporesponsive" or paralyzed state.
Suppression of B Cell Function
In functional assays simulating an active infection, the presence of gp34 led to a near-total blockade of B cell proliferation and differentiation into antibody-secreting plasmablasts. This resulted in a dramatic reduction in the secretion of soluble IgG. Crucially, this effect was not due to cell death, as gp34 did not induce apoptosis; rather, it induced a reversible state of functional impairment.
The Bystander Effect: Indirect Suppression
One of the most significant findings was the observation of a "bystander effect." Although gp34 only binds to IgG⁺ B cells, the researchers observed that neighboring IgM⁺ and IgA⁺ B cells were also suppressed. Further investigation revealed that gp34-stimulated IgG⁺ B cells secrete high levels of TNF-α. This cytokine creates a suppressive microenvironment that inhibits the proliferation and differentiation of nearby B cells that were not directly targeted by the viral protein.
Discussion
This research reveals a sophisticated dual-action strategy employed by HCMV to evade the humoral immune response. By directly targeting IgG⁺ memory B cells, gp34 sabotages the host's secondary immune memory. Simultaneously, by inducing these targeted cells to secrete suppressive factors like TNF-α, the virus extends its reach to suppress the broader B cell compartment, including those cells responsible for primary (IgM) and mucosal (IgA) responses.
This mechanism explains how HCMV can persist and disseminate despite the presence of virus-specific antibodies. The virus essentially turns the host's own memory cells into "traitors" that suppress the rest of the immune response.
Conclusion
The identification of gp34 as a direct modulator of B cell function provides a new perspective on HCMV pathogenesis. Understanding this viral hijacking of the AKT/mTOR pathway and the subsequent bystander suppression offers potential new targets for therapeutic intervention, particularly in clinical settings where HCMV reactivation is a major concern. Future studies will be needed to validate these findings in vivo and explore the long-term impact on the B cell repertoire in chronically infected individuals.
Summary updated